Highlights

  • UiPath joins Veeva AI Partner Program to streamline application testing and validation.
  • Partnership enables digital, audit-ready validation workflows with real-time traceability.
  • Enterprise-grade automation allows end-to-end testing across cloud and on-premises environments.

UiPath (NYSE:PATH) is a global automation leader, enabling enterprises to leverage AI agents for autonomous execution and optimization of complex business processes. The UiPath Platform™ integrates controlled agency, developer flexibility, and seamless system integration to help organizations scale agentic automation safely and efficiently.

UiPath Partners with Veeva for Life Sciences Testing
PATH a global leader in agentic automation, has joined the Veeva AI Partner Program to enhance application testing and validation in life sciences. The collaboration focuses on simplifying highly regulated, manual processes and delivering end-to-end agentic workflows for computer software assurance (CSA) testing and quality management.

Integrated Validation and Testing Workflows
The partnership combines Veeva Validation Management with UiPath Test Manager to create a fully digital, paperless validation workflow. Requirements, test cases, and results are synchronized in real time, ensuring continuous traceability, compliance, and inspection readiness. Teams can generate, execute, and validate requirements with automated pass/fail determinations, all recorded directly within Veeva.

Enterprise-Grade Automation Across Environments
UiPath’s enterprise-grade UI automation enables resilient, self-healing end-to-end testing across both on-premises and cloud systems. A pre-built Veeva API connector, accessible through UiPath Integration Service, allows secure automation of API-driven workflows with standardized authentication and managed rate limits, simplifying scaling across the Veeva ecosystem.

Operational Efficiency and Compliance Focus
The integration is designed to reduce cycle times, lower errors, and improve accuracy while maintaining audit readiness. By linking automated testing with compliance processes, life sciences organizations can manage highly regulated workflows more efficiently and ensure inspection readiness at all times.

Share Performance
The stock closed at USD 18.48 on 4 December 2025, up 24.36% for the day. The stock opened at USD 16.10, reached a high of USD 18.70, and a low of USD 15.75 during the session. Its market capitalization stands at 981.33Cr. The 52-week high is USD 18.74, while the 52-week low is USD 9.38.